A retrospective study of the real-life utilization and effectiveness of ranibizumab therapy for neovascular age-related macular degeneration in the UK

QR Code

A retrospective study of the real-life utilization and effectiveness of ranibizumab therapy for neovascular age-related macular degeneration in the UK

Philip Hykin,1 Usha Chakravarthy,2 Andrew Lotery,3 Martin McKibbin,4 Jackie Napier,5 Sobha Sivaprasad1,6 On behalf of the AURA Study Group 1National Institute for Health Research Biomedical Research Centre in Ophthalmology, Moorfields Eye Hospital, London, UK; 2Institute of Clinical Science, The Qu...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Hykin P, Chakravarthy U, Lotery A, McKibbin M, Napier J, Sivaprasad S
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2016
Sujets:	neovascular or wet age-related macular degeneration treatment medical anti–vascular endothelial growth factor Ophthalmology RE1-994
Accès en ligne:	https://doaj.org/article/fd84137aba1148d3ae55e7a656c76a1c
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Management of neovascular age-related macular degeneration: Taiwan expert consensus
par: Ling Yeung, et autres
Publié: (2021)

Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration
par: Yannuzzi NA, et autres
Publié: (2019)

Vision Recovery Velocity, Momentum and Acceleration: Advanced Vitreoretinal Analytics as Measure of Treatment Efficacy for Neovascular Age-Related Macular Degeneration
par: Almeida DRP, et autres
Publié: (2021)

Treatment of neovascular age-related macular degeneration with anti-VEGF agents: retrospective analysis of 5-year outcomes
par: Pedrosa AC, et autres
Publié: (2016)

Aflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degeneration
par: Balaratnasingam C, et autres
Publié: (2015)

Neovascular age-related macular degeneration without drusen in the fellow eye: clinical spectrum and therapeutic outcome
par: Chung WH, et autres
Publié: (2016)

Neovascular age-related macular degeneration: intraocular inflammatory cytokines in the poor responder to ranibizumab treatment
par: Pongsachareonnont P, et autres
Publié: (2018)

Ten-Year Real-World Outcomes of Anti-Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular Degeneration
par: Cheema MR, et autres
Publié: (2021)

Aflibercept treatment for neovascular AMD beyond the first year: consensus recommendations by a UK expert roundtable panel, 2017 update
par: Patel PJ, et autres
Publié: (2017)

Worsening anatomic outcomes following aflibercept for neovascular age-related macular degeneration in eyes previously well controlled with ranibizumab
par: Nudleman E, et autres
Publié: (2016)

Therapeutic Potential of the Ranibizumab Port Delivery System in the Treatment of AMD: Evidence to Date
par: Chen ER, et autres
Publié: (2020)

Long-Term Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Belgian Subanalysis from the Global Real-World LUMINOUSTM Study
par: Leys AM, et autres
Publié: (2020)

Real-World Effectiveness, Treatment Pattern, and Safety of Ranibizumab in Korean Patients with Neovascular Age-Related Macular Degeneration: Subgroup Analyses from the LUMINOUS Study
par: Sagong M, et autres
Publié: (2021)

Evaluation of contrast sensitivity and other visual function outcomes in neovascular age-related macular degeneration patients after treatment switch to aflibercept from ranibizumab
par: Nixon DR, et autres
Publié: (2017)

Synthetic anti-angiogenic genomic therapeutics for treatment of neovascular age-related macular degeneration
par: Jing Wang, et autres
Publié: (2021)

Patient Preferences Associated with Anti-Vascular Endothelial Growth Factor Therapies for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema
par: Bhagat D, et autres
Publié: (2020)

Side Effects of Brolucizumab
par: Tahmineh Motevasseli, et autres
Publié: (2021)

Quantitative Comparison of the Vascular Structure of Macular Neovascularizations Between Swept-Source and Spectral-Domain Optical Coherence Tomography Angiography
par: Faatz H, et autres
Publié: (2020)

OCT Angiography-based Evaluation of the Choriocapillaris in Neovascular Age-related Macular Degeneration
par: Varsha Pramil, et autres
Publié: (2021)

The Anti-Inflammatory Effect of Hydrogen Gas Inhalation and Its Influence on Laser-Induced Choroidal Neovascularization in a Mouse Model of Neovascular Age-Related Macular Degeneration
par: I-Chia Liang, et autres
Publié: (2021)

Comparison of choroidal neovascularization secondary to white dot syndromes and age-related macular degeneration by using optical coherence tomography angiography
par: Wang JC, et autres
Publié: (2018)

Response of eyes with age-related macular degeneration to anti-VEGF drugs and implications for therapy planning
par: Miyamoto N, et autres
Publié: (2017)

One-year outcome of intravitreal aflibercept injection for age-related macular degeneration resistant to ranibizumab: rapid morphologic recovery and subsequent visual improvement
par: Hirakata T, et autres
Publié: (2016)

Five-year outcomes of intravitreal drug therapy for neovascular age-related macular degeneration in eyes with baseline vision 20/60 or better
par: Khanani AM, et autres
Publié: (2019)

Real-World Outcomes of Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration: A Large-Scale Postmarketing Surveillance in Korea
par: Ryu G, et autres
Publié: (2021)

Twelve-week dosing with Aflibercept in the treatment of neovascular age-related macular degeneration
par: Garweg JG
Publié: (2019)

Incidence of Glaucoma or Ocular Hypertension After Repeated Anti-Vascular Endothelial Growth Factor Injections for Macular Degeneration
par: Wingard JB, et autres
Publié: (2019)

Two-year outcome of treat-and-extend aflibercept after ranibizumab in age-related macular degeneration and polypoidal choroidal vasculopathy patients
par: Azuma K, et autres
Publié: (2018)

Treatment Course of Patients with Exudative Age-Related Macular Degeneration Using Ocular Hypotensives
par: Modjtahedi BS, et autres
Publié: (2020)

Full-thickness macular hole formation following anti-VEGF injections for neovascular age-related macular degeneration
par: Kabanarou SA, et autres
Publié: (2017)

Short-Term Efficacy and Safety Outcomes of Brolucizumab in the Real-Life Clinical Practice
par: Andrea Montesel, et autres
Publié: (2021)

Trends in Real-World Neovascular AMD Treatment Outcomes in the UK
par: Mehta H, et autres
Publié: (2020)

To Peel or Not to Peel: Pars Plana Vitrectomy with Macular Membrane Peel in Eyes with Abnormalities of Vitreomacular Interface and Coexisting Dry Age-Related Macular Degeneration
par: Furashova O, et autres
Publié: (2020)

Are Dilated Fundus Examinations Needed for OCT-Guided Retreatment of Exudative Age-Related Macular Degeneration? A Prospective, Randomized, Pilot Study
par: Solomon SD, et autres
Publié: (2021)

Combination verteporfin photodynamic therapy ranibizumab-dexamethasone in choroidal neovascularization due to age-related macular degeneration: results of a phase II randomized trial
par: Gallemore RP, et autres
Publié: (2017)

Ranibizumab in neovascular age-related macular degeneration: a 5-year follow-up
par: Cvetkova NP, et autres
Publié: (2016)

The Impact of Non-Ophthalmic Factors on Intravitreal Injections During the COVID-19 Lockdown
par: Ashrafzadeh S, et autres
Publié: (2021)

Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe?
par: Dimitrios A Karagiannis, et autres
Publié: (2009)

Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema
par: Fong AH, et autres
Publié: (2013)

Acquired Vitelliform Macular Degeneration: Characteristics and Challenges of Managing Subretinal Fluid
par: Joseph Juliano, et autres
Publié: (2021)